About: COVID-19 infection can cause chemotherapy resistance development in patients with breast cancer and tamoxifen may cause susceptibility to COVID-19 infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 infection can cause chemotherapy resistance development in patients with breast cancer and tamoxifen may cause susceptibility to COVID-19 infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID-19 infection can cause chemotherapy resistance development in patients with breast cancer and tamoxifen may cause susceptibility to COVID-19 infection
Creator	Cure, Erkan Cure, Medine Kadiyoran, Cengiz Vatansev, Hulya
source	Elsevier; Medline; PMC
abstract	Breast cancer is the most common cancer in women and is the second most common cause of death in women. Estrogen plays an important role in breast tumor etiopathogenesis. Tamoxifen and other anti-estrogen drugs are used in breast cancer patients who have a positive estrogen receptor (ER). While angiotensin II plays a key role in breast cancer etiology and causes tamoxifen resistance, angiotensin 1–7 has been reported to may reduce the spread and invasion of breast cancer. During the COVID-19 infection, the virus blocks ACE2, and angiotensin 1–7 production discontinued. Angiotensin III production may increase as angiotensin II destruction is reduced. Thus, aminopeptidase upregulation may occur. Increased aminopeptidase may develop resistance to chemotherapy in breast cancer patients receiving chemotherapy. Estrogen can have a protective effect against COVID-19. Estrogen increase causes ER-α upregulation in T lymphocytes. Thus, estrogen increases the release of interferon I and III from T lymphocytes. Increasing interferon I and III alleviates COVID-19 infection. Tamoxifen treatment causes down-regulation, mutation, or loss in estrogen receptors. In the long-term use of tamoxifen, its effects on estrogen receptors can be permanent. Thus, since estrogen receptors are damaged or downregulated, estrogen may not act by binding to these receptors. Tamoxifen is a P-glycoprotein inhibitor, independent of its effect on estrogen receptors. It suppresses T cell functions and interferon release. We think tamoxifen may increase the COVID-19 risk due to its antiestrogen and P-glycoprotein inhibitory effects.
has issue date	2020-07-09(xsd:dateTime)
bibo:doi	10.1016/j.mehy.2020.110091
bibo:pmid	32663742
has license	no-cc
sha1sum (hex)	17c4c61b6476f7d5a0442758b8d8abbd00cdc44c
schema:url	https://doi.org/10.1016/j.mehy.2020.110091
resource representing a document's title	COVID-19 infection can cause chemotherapy resistance development in patients with breast cancer and tamoxifen may cause susceptibility to COVID-19 infection
has PubMed Central identifier	PMC7347308
has PubMed identifier	32663742
schema:publication	Med Hypotheses
resource representing a document's body	covid:17c4c61b6476f7d5a0442758b8d8abbd00cdc44c#body_text
is schema:about of	named entity 'COVID-19' named entity 'Infection' named entity 'long-term' named entity 'radiotherapy' named entity 'angiotensin II' named entity 'estrogen receptors' named entity 'Aminopeptidase' named entity 'downregulated' named entity 'infusion' named entity 'RAS' named entity 'breast cancer' named entity 'Angiotensin II' named entity 'chemotherapy' named entity 'tamoxifen' named entity 'antiestrogenic' named entity 'COVID-19 infection' named entity 'acute respiratory distress syndrome' named entity 'upregulation' named entity 'chemotherapy' named entity 'breast cancer' named entity 'COVID' named entity 'reduce the spread' named entity 'lung tissue' named entity 'lymphocytes' named entity 'breast tissue' named entity 'infection' named entity 'estrogen receptors' named entity 'virus' named entity 'cell functions' named entity 'ACE2' named entity 'breast cancer' named entity 'AT1' named entity 'ischemic' named entity 'upregulation' named entity 'apoptotic' named entity 'angiotensin' named entity 'vasodilating' named entity 'Angiotensin III' named entity 'breast cancer' named entity 'estrogenic' named entity 'aminopeptidase' named entity 'Tamoxifen' named entity 'tamoxifen' named entity 'infection' named entity 'long-term' named entity 'cardiac damage' named entity 'interferon' named entity 'tumorigenesis' named entity 'anti-inflammatory' named entity 'estrogen' named entity 'tamoxifen' named entity 'tumorigenesis' named entity 'angiotensin' named entity 'estrogen receptors' named entity 'postmenopausal women' named entity 'estrogen' named entity 'endometrium' named entity 'cytosol' named entity 'animal experiment' named entity 'infection' named entity 'vasodilator' named entity 'tamoxifen' named entity 'angiotensin' named entity 'viral load' named entity 'etiology' named entity 'COVID-19' named entity 'Angiotensin' named entity 'tamoxifen' named entity 'ACE2' named entity 'vasodilator' named entity 'breast cancer' named entity 'Estrogen' named entity 'tamoxifen' named entity 'ACE2' named entity 'tamoxifen' named entity 'mutation' named entity 'Tamoxifen' named entity 'breast cancer'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software